Table 1. Associations between Paf15 IOD scores and clinicopathological features in RC IHC samples (n = 105).
| Prognostic variables | No. of cases | Paf15-H in RC¶(%) | P-value (χ2/multi) | Paf15-H in AT§(%) | P-value (χ2/multi) |
|---|---|---|---|---|---|
| Gender | 0.498/0.945 | 0.118/0.388 | |||
| male | 56 | 30 (53.57) | 8(14.29) | ||
| female | 49 | 23 (46.94) | 13(26.53) | ||
| Age | 0.494/0.170 | 0.435/0.978 | |||
| ≥65 | 52 | 28 (53.85) | 12(23.08) | ||
| <65 | 53 | 25 (47.17) | 9(16.98) | ||
| Histological grade | 0.193/0.788 | 0.114/0.050 | |||
| G1-G2 | 26 | 10(38.46) | 8(30.77) | ||
| G3-G4 | 79 | 42(53.16) | 13(16.46) | ||
| Infiltration degree | 0.242/0.231 | 0.272/0.184 | |||
| T1-T2 | 21 | 13(61.90) | 6(28.57) | ||
| T3-T4 | 84 | 40(47.62) | 15(17.86) | ||
| Lymph node metastasis | 0.0001*/0.337 | 0.373/0.999 | |||
| + | 44 | 11(25.00) | 7(15.91) | ||
| - | 61 | 42(68.85) | 14(22.95) | ||
| pTNM Stage | 0.0001*/0.0001* | 0.279/0.999 | |||
| I-II | 46 | 12(26.09) | 14(23.73) | ||
| III-IV | 59 | 41(69.49) | 7(15.22) | ||
| Tumor size | 0.944/0.004* | 0.918/0.777 | |||
| <15cm3 | 36 | 18(50.00) | 7(19.44) | ||
| ≥15cm3 | 69 | 35(50.72) | 14(20.29) |
*
Correlation significant at the 0.01 level (two tailed); pTNM, pathological tumor/node/metastasis; multi, multivariate logistic regression analysis.
¶
Number of Paf15 high expression (IOD > median) cases and the percentage in RC tissues.
§
Number of Paf15 high expression (IOD > median) cases and the percentage in matched adjacent non-cancerous rectal tissues.